Journal
RESPIRATORY MEDICINE
Volume 106, Issue -, Pages S9-S19Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/S0954-6111(12)70005-7
Keywords
Airways; Combination therapy; Bronchodilators; Glucocorticosteroids; Fluticasone propionate; Formoterol fumarate; ICS/LABA; Pharmacological profiles
Funding
- Mundipharma International Limited (Cambridge, UK)
- Mundipharma International Limited
- AstraZeneca
- Boehringer Ingelheim
- Chiesi Farmaceutici
- GlaxoSmithKline
- Italian Ministry of Health
- Italian Ministry for University and Research
- Menarini Industrie Farmaceutiche
- Merck Sharp Dhome
- Novartis
- Nyconned
- Pfizer
- Roche
- Sigma-Tau
Ask authors/readers for more resources
Fixed-dose combinations of inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) have been used to manage asthma for several years. They are the preferred therapy option for patients who do not achieve optimal control of their asthma with low-dose ICS nnonotherapy. In Europe, four ICS/LABA products are commercially available for asthma maintenance therapy (fluticasone propionate/formoterol fumarate, fluticasone propionate/salmeterol xinafoate, budesonide/formoterol fumarate and beclometasone dipropionate/formoterol fumarate), and other combinations are likely to be developed over the next few years (e.g. mometasone/formoterol fumarate, fluticasone furoate/ vilanterol, mometasone/indacaterol). Data from randomized, controlled, clinical trials do not demonstrate a clear overall efficacy difference among ICS/LABA combinations approved for asthma therapy. Conversely, pharmacological data indicate that there may be certain advantages to using one ICS or LABA over another because of the specific pharmacodynamic and pharmacokinetic profiles associated with particular treatments. This review article summarizes the pharmacological characteristics of the various ICSs and LABAs available for the treatment of asthma, including the potential for ICS and LABA synergy, and gives an insight into the rationale for the development of the latest ICS/LABA combination approved for asthma maintenance therapy. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available